echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > PNAS: a key gene that leads to cancer resistance

    PNAS: a key gene that leads to cancer resistance

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A researcher at the University of Missouri School of Medicine has discovered an enzyme that plays a key role in the ability of cancer cells to resist drug treatments


    Immunomodulatory drugs such as thalidomide, lenalidomide and premalidomide have improved the treatment of patients with multiple myeloma and other blood cancers


    Dr.


    Nguyen said: "This USP15 protein protects cancer cells from destruction by removing the ubiquitin tags placed on cells by immunomodulatory drugs


    Nguyen believes that the USP15 test for patients with multiple myeloma will help determine whether the patient will develop resistance to immunomodulatory drug therapy


    Nguyen said: "This work can lead us to discover whether the combination of USP15 inhibitors and other drugs will be more effective in treating cancer


    "USP15 antagonizes CRL4 CRBN a-mediated ubiquitylation of glutamine synthetase and neo-substrates,"was published in the journalProceedings of the National Academy of Sciences of the United States of America.
     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.